Ultragenyx RARE shares ended the last trading session 5.1% higher at $41.44. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 5.1% gain over the past four weeks.
The sudden rise in the stock price can be attributed to the positive investor mindset regarding Ultragenyx’s key late-stage pipeline progress. A regulatory application, seeking the FDA approval of UX111, an AAV gene therapy candidate being developed for the treatment of patients with Sanfilippo syndrome type A, is currently under Priority Review. A final decision is expected on Aug. 18, 2025. Ultragenyx is also planning to submit a biologics license application for its investigational AAV8 gene therapy, DTX401, to treat glycogen storage disease type Ia soon. If approved, sales of these drugs will provide RARE with additional sources of revenue.
This biotechnology company is expected to post quarterly loss of $1.27 per share in its upcoming report, which represents a year-over-year change of +16.5%. Revenues are expected to be $161.61 million, up 9.9% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Ultragenyx, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on RARE going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Ultragenyx belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Fortress Biotech FBIO, closed the last trading session 3.1% higher at $1.99. Over the past month, FBIO has returned -7.2%.
For Fortress Biotech, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.31. This represents a change of +57.5% from what the company reported a year ago. Fortress Biotech currently has a Zacks Rank of #3 (Hold).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Ultragenyx Pharmaceutical Inc. (RARE): Free Stock Analysis Report Fortress Biotech, Inc. (FBIO): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
